Avalon BioVentures SPV I, L.P., 10% Owner at Janux Therapeutics, Inc. (JANX), sold 2,784,532 shares at $44.75 ($129.7M) on 2024-10-18, disclosed to the SEC on 2024-10-18.
Open-market sale of $129.7M JANX by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.69 | 61,445 | $3.1M | 2.4% |
| 2 | $49.69 | 61,445 | $3.1M | 2.4% |
| 3 | $49.69 | 11,657 | $579K | 0.4% |
| 4 | $49.69 | 11,657 | $579K | 0.4% |
| 5 | $49.69 | 60,179 | $3.0M | 2.3% |
| 6 | $49.69 | 60,179 |
| $3.0M |
| 2.3% |
| 7 | $50.61 | 5,710 | $289K | 0.2% |
| 8 | $50.61 | 5,710 | $289K | 0.2% |
| 9 | $50.61 | 29,474 | $1.5M | 1.2% |
| 10 | $50.61 | 29,474 | $1.5M | 1.2% |
| 11 | $50.61 | 30,094 | $1.5M | 1.2% |
| 12 | $50.61 | 30,094 | $1.5M | 1.2% |
| 13 | $50.80 | 10,957 | $557K | 0.4% |
| 14 | $50.80 | 10,957 | $557K | 0.4% |
| 15 | $50.02 | 1,843 | $92K | 0.1% |
| 16 | $50.02 | 1,843 | $92K | 0.1% |
| 17 | $44.75 | 553,219 | $24.8M | 19.1% |
| 18 | $44.75 | 104,957 | $4.7M | 3.6% |
| 19 | $44.75 | 104,957 | $4.7M | 3.6% |
| 20 | $44.75 | 541,824 | $24.2M | 18.7% |
| 21 | $44.75 | 553,219 | $24.8M | 19.1% |
| 22 | $50.30 | 104,892 | $5.3M | 4.1% |
| 23 | $50.30 | 104,892 | $5.3M | 4.1% |
| 24 | $50.30 | 19,900 | $1.0M | 0.8% |
| 25 | $50.30 | 102,732 | $5.2M | 4.0% |
| 26 | $50.30 | 102,732 | $5.2M | 4.0% |
| 27 | $51.18 | 15,788 | $808K | 0.6% |
| 28 | $51.18 | 15,788 | $808K | 0.6% |
| 29 | $51.18 | 2,995 | $153K | 0.1% |
| 30 | $51.18 | 2,995 | $153K | 0.1% |
| 31 | $51.18 | 15,462 | $791K | 0.6% |
| 32 | $51.18 | 15,462 | $791K | 0.6% |
| Total | $46.58 avg | 2,784,532 | $129.7M | 100% |